Published in Drug Week, May 26th, 2006
The phase 2a safety study has been reviewed and approved by both the U.S. Food and Drug Administration (FDA) and by the institutional review board (IRB) of the University of California, Irvine (UCI). The study will be conducted by Steven Cramer, a stroke specialist at UCI.
Patient screening for this open label study, expected to enroll approximately 12 subjects, is anticipated to begin in the near...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.